SCHEMBL4008934

SCHEMBL4008934

O=C(CCl)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.63
HTT P42858 3/20 0.61
LMNA P02545 2/20 0.61
L3MBTL1 Q9Y468 1/20 0.59
KCNJ5 P48544 1/20 0.59
KCNJ3 P48549 1/20 0.59
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
MITF O75030 2/20 0.58
XBP1 P17861 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
NOD2 Q9HC29 1/20 0.58
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
ALDH1A1 P00352 3/20 0.56
PRMT1 Q99873 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
KIF11 P52732 1/20 0.54
TGM2 P21980 1/20 0.54
RHOC P08134 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23748592 0.91 RNF4 (0.68) EPHX2HTTLMNAL3MBTL1KCNJ5
SCHEMBL5142584 0.86 EPHX2 (0.70) EPHX2HTTLMNAL3MBTL1KCNJ5
SCHEMBL11817205 0.86 EPHX2 (0.59) EPHX2HTTLMNAL3MBTL1KCNJ5
SCHEMBL9081388 0.84 NPC1 (0.76) HTTLMNAL3MBTL1NPC1RAB9A
SCHEMBL2094723 0.83 EPHX2 (0.66) EPHX2HTTLMNAL3MBTL1KCNJ5
SCHEMBL9185912 0.83 EPHX2 (0.66) EPHX2HTTLMNAL3MBTL1KCNJ5
SCHEMBL2094720 0.83 EPHX2 (0.66) EPHX2HTTLMNAL3MBTL1KCNJ5
SCHEMBL8180976 0.82 EPHX2 (0.54) EPHX2HTTLMNAL3MBTL1KCNJ5
SCHEMBL263685 0.81 LMNA (0.65) LMNAALDH1A1RHOCRHOAMAPT
SCHEMBL2056170 0.81 EPHX2 (0.63) EPHX2HTTLMNAL3MBTL1KCNJ5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118126030-A Preparation method of pyrazoline-1, 3, 4-oxadiazole thioacetamide derivative and application of pyrazoline-1, 3, 4-oxadiazole thioacetamide derivative as pesticide 贵州大学 2024-06-04 CN disclosed
EP-4326721-A1 SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS Protego Biopharma, Inc. (US) 2024-02-28 EP disclosed
US-20240051960-A1 SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS PROTEGO BIOPHARMA, INC. 2024-02-15 US disclosed
CN-110372531-B Ether acetamide derivative containing alpha-carbonyl amide structure and application thereof 贵州大学 2023-03-21 CN disclosed
WO-2022226166-A1 SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS PROTEGO BIOPHARMA, INC. (US) 2022-10-27 WO disclosed
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-02 US disclosed
CN-107400088-B 1, 3-disubstituted pyrazole derivatives, and preparation method and application thereof 山东大学 2020-04-28 CN disclosed
US-20200054651-A1 COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-02-20 US disclosed
US-20200054651-A1 COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-02-20 US disclosed
CN-110785426-A Compositions and methods for modulating PPP2R1A 加利福尼亚大学董事会 2020-02-11 CN disclosed
US-20050096376-A1 Substituted 3-pyrrolidine-indole derivatives GRUENENTHAL GMBH (DE) 2005-05-05 US disclosed
WO-2005019208-A1 SUBSTITUTED 3-PYRROLIDIN-INDOLE DERIVATIVES Grünenthal GmbH (DE) 2005-03-03 WO disclosed
EP-1509213-A2 ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION Abbott Laboratories (US) 2005-03-02 EP disclosed
US-20040029887-A1 Acetamides and benzamides that are useful in treating sexual dysfunction ABBOTT LABORATORIES 2004-02-12 US disclosed
US-20030229094-A1 Acetamides and benzamides that are useful in treating sexual dysfunction ABBOTT LABORATORIES 2003-12-11 US disclosed
WO-2003099266-A2 ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION ABBOTT LABORATORIES (US) 2003-12-04 WO disclosed
US-4567264-A ADRENERGIC BLOCKING AGENTS SYNTEX (U.S.A.) INC. (US) 1986-01-28 US disclosed
US-4558129-A Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade SYNTEX (U.S.A.) INC. (US) 1985-12-10 US disclosed
US-4499100-A CARDIOUVASCULAR DISORDERS SYNTEX (U.S.A.) INC. (US) 1985-02-12 US disclosed
EP-0126449-A1 Cardioselective aryloxy- and arylthio-hydroxypropyl piperazinyl acetanilides wich affect calcium entry SYNTEX (U.S.A.) INC. (US) 1984-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229094-A1 Acetamides and benzamides that are useful in treating sexual dysfunction CATSPER1, CYP19A1, PDE12 EPHX2 1688/4885HTT 4561/4885LMNA 4331/4885
US-20040029887-A1 Acetamides and benzamides that are useful in treating sexual dysfunction CATSPER1, CYP19A1, PDE12 EPHX2 1688/4885HTT 4561/4885LMNA 4331/4885
US-20240051960-A1 SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS IGLV6-57, TTR, MAP1LC3C EPHX2 4718/4885HTT 154/4885LMNA 109/4885
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES RNF114, RNF4, RNF168 EPHX2 4228/4885HTT 546/4885LMNA 3321/4885
US-20050096376-A1 Substituted 3-pyrrolidine-indole derivatives OPRD1, OPRK1, TPH1 EPHX2 3622/4885HTT 358/4885LMNA 3265/4885
US-20200054651-A1 COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A PPP2R1A, PPP3CA, PPP2R2A EPHX2 4285/4885HTT 2415/4885LMNA 3160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.